Phase 3 Readout

GTBP: Phase 3 Topline: A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizu

Name: Phase 3 Topline: A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizu
Start: 2031-01-23
End: 2031-01-23

January 23, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 23, 2031
Company: GT Biopharma, Inc. (GTBP)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Open-Label, Extension Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizu

January 23, 2031

GTBP overview →

Company: GT Biopharma, Inc. (GTBP)
Indication: Ocular Myasthenia Gravis